<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236427</url>
  </required_header>
  <id_info>
    <org_study_id>ANP study</org_study_id>
    <nct_id>NCT04236427</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Angong Niuhuang Wan for Stroke</brief_title>
  <official_title>Efficacy and Safety of Chinese Medicine Angong Niuhuang Wan for the Treatment of the Stroke: A Randomized, Double-blind,Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of using Chinese Medicine Angong Niuhuang Wan in stroke&#xD;
      patients, the modified Rankin Scale (mRS) score will be used as primary outcome, the National&#xD;
      Institutes of Health Stroke Scale (NIHSS) score, The Modified Barthel Index (MBI) score and&#xD;
      the Montreal Cognitive Assessment (MoCA) scores will be used as secondary outcome measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled trial which is used to further&#xD;
      determine the effectiveness of Angong Niuhuang Wan in treating stroke patients on top of the&#xD;
      standard conventional treatment, also to evaluate the improvement level on quality of life of&#xD;
      post-stroke after using Angong Niuhuang Wan. The effect of Angong Niuhuang Wan on liver and&#xD;
      kidney function will be focused and using NMR techniques to analysis metabolomics to further&#xD;
      study the safety and effectiveness of Angong Niuhuang Wan on the prevention and treatment of&#xD;
      stroke.&#xD;
&#xD;
      It is a 24-week trial, Double-blind treatment for 1 week, follow up visit for 23 weeks. All&#xD;
      participant will have study blood taking for renal and liver function test and questionnaires&#xD;
      assessment during study visits. Informed consent will be obtained before study enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score of neurological deficit and adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>compare the therapeutic effects, the score of neurological deficit and adverse events between the two groups by using questionnaire of mRS, higher scores mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality and recurrence rates of stroke</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compare the mortality and recurrence rates of stroke between two groups also the abilities of daily ability using questionnaires of NIHSS (higher scores mean a worse outcome), mBI and MOCA-HK (higher scores mean a better outcome)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stroke (CVA) or TIA</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chinese Medicine of Angong Niuhuang Wan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Angong Niuhuang Wan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angong Niuhuang Wan</intervention_name>
    <description>Angong Niuhuang Wan 3g</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Active drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angong Niuhuang Wan Placebo</intervention_name>
    <description>Angong Niuhuang Wan Placebo 3g</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chinese adults aged 40 or above;&#xD;
&#xD;
          2. diagnosed as a stroke by a neurologist, with imaging of CT or MRI support;&#xD;
&#xD;
          3. Neurologist confirms the symptoms of stroke occur within 28 days and are clinically&#xD;
             stable. In the past 48 hours, the condition of the nervous system has not deteriorated&#xD;
             significantly;&#xD;
&#xD;
          4. TCM diagnosis is a stroke and belongs to a heat syndrome;&#xD;
&#xD;
          5. There is a movement defect caused by stroke;&#xD;
&#xD;
          6. The severity of stroke was scored 5-25 by the National Institutes of Health Brain&#xD;
             Stroke Scale (NIHSS);&#xD;
&#xD;
          7. Informed consent will be given by participant or its representatives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The movement defects are not associated with stroke. Before commencement of study&#xD;
             treatment, patient has physical activity dysfunction caused by lameness ,&#xD;
             osteoarthritis, rheumatoid arthritis, gouty arthritis, etc. that may affect&#xD;
             neurological function examination;&#xD;
&#xD;
          2. Subjects are unlikely to come back for follow-up visits during the 24-week study&#xD;
             period;&#xD;
&#xD;
          3. The subject has a brain tumor on a computed tomography scan (CT);&#xD;
&#xD;
          4. The subject has thrombocytopenia (known platelet count &lt;100,000 / mm3) or coagulopathy&#xD;
             disease;&#xD;
&#xD;
          5. Taking warfarin or other anticoagulant;&#xD;
&#xD;
          6. Concomitant diseases such as severe hypertension or diabetes;&#xD;
&#xD;
          7. Comorbidities or complications associated with drug evaluation;&#xD;
&#xD;
          8. Pregnant or breast-feeding female.&#xD;
&#xD;
          9. The alanine aminotransferase (ALT) value is 1.5 times higher than the normal maximum&#xD;
             value in liver function test and the estimated glomerular filtration rate (eGFR) &lt;30&#xD;
             ml/min/1.73 m2 in the renal function test.&#xD;
&#xD;
         10. Present the sign of pure yin syndrome or yin / yang defecation in TCM diagnosis;&#xD;
&#xD;
         11. Subject has G6PD&#xD;
&#xD;
         12. Known swallowing problem&#xD;
&#xD;
         13. Dependent in all daily life activities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Yuk-lun LAU, Post-doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Yuk-lun LAU, Post-doc</last_name>
    <phone>3505 3476</phone>
    <email>alexlau@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pui Kuan Cheong, MPH</last_name>
    <phone>3505 3476</phone>
    <email>jcheong@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Lau, Post-doc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Alexander Lau</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

